Organon & Co. (NYSE:OGN) Shares Acquired by Brandes Investment Partners LP

Brandes Investment Partners LP lifted its holdings in shares of Organon & Co. (NYSE:OGN) by 5.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 204,722 shares of the company’s stock after acquiring an additional 11,051 shares during the period. Brandes Investment Partners LP owned 0.08% of Organon & Co. worth $4,236,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its holdings in Organon & Co. by 200.2% during the second quarter. Versant Capital Management Inc now owns 1,207 shares of the company’s stock worth $25,000 after purchasing an additional 805 shares in the last quarter. William B. Walkup & Associates Inc. purchased a new position in shares of Organon & Co. in the 2nd quarter valued at $31,000. Atlas Capital Advisors LLC raised its stake in Organon & Co. by 2,236.5% during the 2nd quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock worth $46,000 after acquiring an additional 2,147 shares in the last quarter. Fidelis Capital Partners LLC purchased a new stake in Organon & Co. in the first quarter valued at $43,000. Finally, Tompkins Financial Corp boosted its stake in Organon & Co. by 450.7% in the first quarter. Tompkins Financial Corp now owns 2,412 shares of the company’s stock valued at $45,000 after acquiring an additional 1,974 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of OGN opened at $19.12 on Tuesday. The company has a debt-to-equity ratio of 60.05, a quick ratio of 1.17 and a current ratio of 1.64. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $23.10. The firm has a 50-day simple moving average of $20.79 and a 200-day simple moving average of $20.16. The company has a market capitalization of $4.92 billion, a price-to-earnings ratio of 4.67, a price-to-earnings-growth ratio of 0.87 and a beta of 0.85.

Organon & Co. (NYSE:OGN) last announced its earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.04. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The company had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.61 billion. During the same period last year, the business posted $1.31 EPS. The company’s revenue was down .1% on a year-over-year basis. On average, equities research analysts anticipate that Organon & Co. will post 4.14 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Shareholders of record on Friday, August 16th were given a dividend of $0.28 per share. The ex-dividend date was Friday, August 16th. This represents a $1.12 dividend on an annualized basis and a yield of 5.86%. Organon & Co.’s payout ratio is currently 27.38%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on OGN. Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. cut Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their price objective for the company from $18.00 to $20.00 in a research note on Friday, September 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Organon & Co. has a consensus rating of “Hold” and an average target price of $21.00.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.